The use of eculizumab for renal transplantation in children

Ischemia reperfusion injury (IRI) is an inevitable consequence of kidney transplantation. Activation of the terminal complement complex C5b-9 was detected in experimental and clinical organ transplantation. Ekulizumab is a monoclonal antibody that blocks the terminal component of the complement activation. We reported our preliminary results on evaluating the impact of ekulizumab on IRI.

2. Takada M., Nadeau K. C., Shaw G. D. et al. Cytokine-adhesion molecule cascade in ischemia/reperfusion injury in the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest. 1997; Vol. 99: 2682-90.

3. Chen G., Chen S., Chen X. Role of complement and perspectives for intervention in transplantation. Immunology. 2013; Vol. 218: 817-27.

4. De Vries D. K., Van Der Pox P., Van Anken G. E. et al. Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. Transplantation. 2013; Vol. 95: 816-20.

5. Lu CY ., Penfeld J. G., Kielar M. I. et al. Is renal allograft rejection initiated by the response to injury sustained during the transplant process? Kidney Int. 1999; Vol. 55: 2157-68.

6. Damman J., Seelen M. A., Moers C. et al. Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient. Transplantation. 2011; Vol. 92: 163-9.

8. Hillmen P., Young N. S., Schubert J. et al. The complement inhibitor Eculizumab in paroxysmal nocturnal haemoglobinuria. N Engl J Med. 2006; Vol. 355: 1233-43.

9. Gruppo R.A., Ruther R.P. Eculizumab for congenital atypical hemolitico-uremical syndrome. N Engl J Med. 2009; Vol. 360: 544-6.

10. Stegall M. D., Diwan T., Raghavaman S. et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011; Vol. 11: 2405-13.

11. Biglarnia A. R., Nillson B., Nillson R. et al. Prompt reversal of severe complement activation by Eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transplant Int. 2011; Vol. 24: c61-c66.

12. Burbach M., Suberbielle C., Quali N. et al. Report on inefficacy of Eculizumab in two cases of severe antibody mediated rejection of renal grafts [abstract]; 16th Congress of the European Society for organ transplantation. 2013 September 8-11. Abstracts BO259.

13. Ait B. D., Susal C., Gebel H. M. et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013; Vol. 95: 19-47.